Subsequent Events |
3 Months Ended |
|---|---|
Mar. 31, 2016 | |
| SUBSEQUENT EVENTS | |
| SUBSEQUENT EVENTS |
11. Subsequent Events
On April 11, 2016, the Company was awarded a research and development grant of approximately $1.0 million from the National Institute on Drug Abuse at the National Institutes of Health. The grant provides the Company with additional resources for the ongoing Phase 2 clinical trial of CERC-501. The Company expects to receive the grant amount during the second quarter of 2016.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. No definition available.
|